Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

α2A-Adrenergic Receptor Inhibits the Progression of Cervical Cancer Through Blocking PI3K/AKT/mTOR Pathway

Weina Wang1, Xin Guo2, Huiwen Dan2

  • 1Health Management Center, Qingdao Sixth People's Hospital, Qingdao, Shandong 266011, People's Republic of China.

Oncotargets and Therapy
|October 29, 2020
PubMed
Abstract

Insights

The alpha-2A adrenergic receptor (ADRA2A) is downregulated in cervical cancer, suppressing tumor growth and progression. Its restoration inhibits proliferation and promotes apoptosis by modulating the PI3K/Akt/mTOR pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cervical cancer remains a significant global health challenge.
  • The role of specific adrenergic receptors in cervical cancer pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the expression and function of the alpha-2A adrenergic receptor (ADRA2A) in cervical cancer.
  • To elucidate the underlying molecular mechanisms, particularly the involvement of the PI3K/Akt/mTOR pathway.

Main Methods:

  • Analysis of public RNA sequencing datasets (GEPIA, TCGA) for ADRA2A expression and prognostic value.
  • qRT-PCR and Western blot to assess ADRA2A levels in cell lines.
  • In vitro assays evaluating cell proliferation, apoptosis, migration, invasion, and senescence.
  • In vivo tumorigenesis studies in nude mice.
  • Investigation of PI3K/Akt/mTOR pathway activation following ADRA2A manipulation.

Main Results:

  • ADRA2A expression is significantly downregulated in cervical cancer tissues and cell lines.
  • Higher ADRA2A expression correlates with improved patient prognosis.
  • ADRA2A overexpression inhibits proliferation, migration, and invasion while promoting apoptosis and senescence.
  • ADRA2A silencing exhibits opposite effects.
  • ADRA2A modulates the PI3K/Akt/mTOR pathway, decreasing phosphorylation of key components.
  • ADRA2A overexpression suppresses xenograft tumor growth in vivo.

Conclusions:

  • ADRA2A acts as a tumor suppressor in cervical cancer.
  • ADRA2A inhibits cervical cancer progression by suppressing proliferation, migration, and invasion.
  • These effects are mediated through the inhibition of the PI3K/Akt/mTOR signaling pathway.
Keywords:
ADRA2API3K/Akt/mTOR pathwaycervical cancermetastasisproliferationsenescence

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.6K